Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Citizens JMP Life Sciences Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 07, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 06, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
April 24, 2024 16:35 ET | Source: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
March 26, 2024 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination...
March 19, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
March 07, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug...
December 20, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
December 13, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and...
December 06, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...